Skip to main content
. 2018 Mar 30;9(24):16832–16846. doi: 10.18632/oncotarget.24709

Figure 4. BRAFi/MEKi combination affects diffusional heterogeneity in sensitive melanoma xenografts.

Figure 4

Skewness (A–C) and kurtosis (B–D) of the ADC distribution are represented as absolute differences from baseline (mean ± SEM). Both skewness (*p = 0.0210 vs day 0, n = 4–9/group) and kurtosis (*p = 0.0103 at day 2, p = 0.0229 at day 5 vs day 0, n = 4–9/group) decreased following combined BRAF/MEK inhibition in BRAFi-sensitive (A–B), but not in BRAFi-resistant (C–D) melanoma xenografts (n = 4/group).